My friend and fellow integrative physician and pharmacist Richard Harris MD, PharmD, MBA does a great job producing g these little nuggets from recent studies. I highly recomend you follow if you're interested in evidence-based research and clinical application 💯 🤓 This particular study he covers is especially interesting to me since it is about continuous glucose monitors (CGMs) and especially relevent with the recent release of the OTC Stelo by Dexcom. Some of you may have heard me talk about using CGMs - which track blood sugar fluctuations 24/7 for a period of 2 weeks using a monitor you insert usually into your arm. ✨️ They can be so helpful in making connections between blood sugar fluctuations and symptoms like fatigue, insomnia, brain fog. This can help guide diet and lifestyle habits that influence them. The problem 👉🏽 there's no established guidance on how to use them outside of diabetes ranges. That means it takes some special training and skill to use the information in a practical way. 🤓 I appreciate the expanded access is convenient, I also agree with Dr Harris that it's still really important to use in collaboration with a clinician that knows how to interpret the data. What do you think about CGMs? Let's keep the conversation going in the comments 👇🏽 #glucosemonitor #bloodsugar #dexcom #pharmacist #lifestylemedicine
Defining Continuous Glucose Monitor Time in Range in a Large, Community-Based Cohort Without Diabetes PMID: 39257191 https://lnkd.in/gtJNtQwD I don't think individuals without some form of insulin resistance (diabetes, prediabetes) need to use a CGM, but the cat is out of the bag. It would be helpful to have guidance that correlates what is seen on 24-hour CGM data to blood work levels for average glucose, prediabetes, and diabetes. This study took participants from the Framingham heart study and had them wear a Dexcom for at least 7 full days. Diabetes and prediabetes criteria were based on A1c, fasting glucose, and self-report of diabetes or taking glucose-lowering medications. 12.9% of participants had diabetes, 39.4% prediabetes, and 47.7% normoglycemia. Those with normoglycemia spent less than 15 min/dL above blood glucose of 180 mg/dl and about 3 hours per day above 140 mg/dL. Those with prediabetes spent about 45 min/d above 180 mg/dL and 5 and a quarter hours per day above 140 mg/dL. The individuals with diabetes spent 6.5 hours per day above 180 mg/dL and 13.5 hours per above 140 mg/dL. This study was cross-sectional and, therefore, cannot say whether time spent in specific glucose ranges increases the risk of diabetes. We hope to get future studies that look at this. However, the key takeaway is that people with normal glycemic responses can still have "glucose spikes". These breakpoints can be used to help guide OTC consumers who use a CGM and have questions about what their values mean. #nimbushealthcare #nimbushealtclub #glucose #glucosespikes #cgm #diabetes #insulin #insulinresistance #health #wellness #doctor